CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain.
Poster Presentations:
| Title: | Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors |
| Presentation #: | 483P |
| Date: | Saturday, September 28 |
| Time: | 12:00 – 13:00 CEST |
| Location: | Poster Area (Hall 4) |
| Presenter: | Chi-Yuan Wu, Ph.D., BeiGene |
| Title: | Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors |
| Presentation #: | 482P |
| Date: | Saturday, September 28 |
| Time: | 12:00 – 13:00 CEST |
| Location: | Poster Area (Hall 4) |
| Presenter: | Chi-Yuan Wu, Ph.D., BeiGene |
| Title: | Updated Results of the PARP1/2 Inhibitor Pamiparib in Combination with Low-dose Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors |
| Presentation #: | 451PD |
| Date: | Saturday, September 28 |
| Time: | 16:30 – 18:00 CEST |
| Location: | Alicante Auditorium (Hall 3) |
| Presenter: | Agostina Stradella, M.D., Catalan Institute of Oncology, Spain |
| Title: | Safety, Antitumor Activity, and Pharmacokinetics of Pamiparib, a PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors: Updated Phase 1 Dose-Escalation/Expansion Results |
| Presentation #: | 452PD |
| Date: | Saturday, September 28 |
| Time: | 16:30 – 18:00 CEST |
| Location: | Alicante Auditorium (Hall 3) |
| Presenter: | Mark Voskoboynik, MBBS, FRACP, Nucleus Network, Australia |
| Title: | First Report of Efficacy and Safety from a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma in Asian Patients |
| Presentation #: | 920P |
| Date: | Monday, September 30 |
| Time: | 12:00 – 13:00 CEST |
| Location: | Poster Area (Hall 4) |
| Presenter: | Dingwei Ye, M.D., Ph.D., Fudan University Cancer Institute, China |
| | |
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1
| | |
| Investor Contact | Media Contact |
| Craig West | Liza Heapes |
| +1 857-302-5189 | +1 857-302-5663 |
| ir@beigene.com | media@beigene.com |
1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.